[PDF][PDF] An update on pregnancy outcomes following ocrelizumab treatment in patients with multiple sclerosis and other autoimmune diseases
S Wray, L Kappos, S Vukusic… - Poster presented at …, 2017 - cmsc.confex.com
BACKGROUND• Ocrelizumab (OCR), a humanized monoclonal antibody that selectively
targets CD20+ B cells, is approved by the US Food and Drug Administration and the …
targets CD20+ B cells, is approved by the US Food and Drug Administration and the …
Immunotherapeutics in pediatric autoimmune central nervous system disease: agents and mechanisms
Beyond the major advances produced by careful clinical-radiological phenotyping and
biomarker development in autoimmune central nervous system disorders, a comprehensive …
biomarker development in autoimmune central nervous system disorders, a comprehensive …
[HTML][HTML] Esclerosis múltiple de alta actividad:¿ se puede iniciar precozmente el tratamiento con drogas de alta eficacia?
C Huamaní, E Rojas, J Inca - Acta Médica Peruana, 2017 - scielo.org.pe
La esclerosis múltiple (EM) es una enfermedad crónica del sistema nervioso central (SNC)
que desarrolla cuadros clínicos muy variados, puede progresar con brotes, dejar secuelas …
que desarrolla cuadros clínicos muy variados, puede progresar con brotes, dejar secuelas …
[HTML][HTML] How far away from having an effective treatment option for progressive multiple sclerosis are we?
A Sartori, J Fantini, P Manganotti - Expert opinion on …, 2017 - Taylor & Francis
The availability of numerous disease-modifying drugs for relapsing-remitting (RR) multiple
sclerosis (MS) is one of the greatest successes of the last 30 years of neurology history …
sclerosis (MS) is one of the greatest successes of the last 30 years of neurology history …
Biotherapy in inflammatory diseases of the CNS: Current knowledge and applications
N Collongues, L Michel, J de Seze - Current treatment options in …, 2017 - Springer
Opinion statement Biotherapy represents an innovative therapeutic approach that includes
immunotherapy (vaccines, apheresis, and antibodies); gene therapy; and stem cell …
immunotherapy (vaccines, apheresis, and antibodies); gene therapy; and stem cell …
[HTML][HTML] Evidence of disease control: a realistic concept beyond NEDA in the treatment of multiple sclerosis
AC Londoño, CA Mora - F1000Research, 2017 - ncbi.nlm.nih.gov
Although no evidence of disease activity (NEDA) permits evaluation of response to treatment
in the systematic follow-up of patients with multiple sclerosis (MS), its ability to accomplish …
in the systematic follow-up of patients with multiple sclerosis (MS), its ability to accomplish …
Daclizumab for the treatment of multiple sclerosis
A Papadopoulou, T Derfuss… - Neurodegenerative …, 2017 - Taylor & Francis
Daclizumab is a monoclonal antibody that targets the α-chain of the IL-2 receptor. Results of
Phase II and III clinical trials showed efficacy of daclizumab in relapsing-remitting multiple …
Phase II and III clinical trials showed efficacy of daclizumab in relapsing-remitting multiple …
[HTML][HTML] Атрофия головного мозга и эффективность препаратов патогенетической терапии при рассеянном склерозе
ИД Столяров, АМ Петров, МВ Вотинцева - Нервные болезни, 2017 - cyberleninka.ru
В статье обсуждается проблема атрофического процесса в головном мозге у
пациентов с рассеянным склерозом (РС) и возможности воздействия на него …
пациентов с рассеянным склерозом (РС) и возможности воздействия на него …
Advancing trial design in progressive multiple sclerosis
DH Miller, AJ Thompson - Multiple Sclerosis Journal, 2017 - journals.sagepub.com
Fox. Development of the content was assisted from notes made during the workshop by
Carmen Tur and Daniel Ontaneda. Authors of the papers were also workshop participants …
Carmen Tur and Daniel Ontaneda. Authors of the papers were also workshop participants …